Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Concurrent atazanavir and voriconazole in a patient with multidrug-resistant HIV and a mycetoma.
Gibson JN, Fulco PP.
AIDS. 2011 Oct 23;25(16):2054-6. No abstract available.
Related citations
Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
Smith RA, Raugi DN, Kiviat NB, Hawes SE, Mullins JI, Sow PS, Gottlieb GS; University of Washington-Dakar HIV-2 Study Group.
AIDS. 2011 Nov 28;25(18):2235-41.
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, van Delft Y, Marks S.
AIDS. 2011 Nov 28;25(18):2249-58.
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
Soriano V, Sherman KE, Rockstroh J, Dieterich D, Back D, Sulkowski M, Peters M.
AIDS. 2011 Nov 28;25(18):2197-208. Review.
Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.
Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, Montavon C, Mpoudi-Ngole E, Delaporte E, Peeters M.
AIDS. 2011 Nov 13;25(17):2183-8.
Switching between raltegravir resistance pathways analyzed by deep sequencing.
Mukherjee R, Jensen ST, Male F, Bittinger K, Hodinka RL, Miller MD, Bushman FD.
AIDS. 2011 Oct 23;25(16):1951-9.
Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy.
Llibre JM, Arribas JR, Domingo P, Gatell JM, Lozano F, Santos JR, Rivero A, Moreno S, Clotet B; Spanish Group for FDAC Evaluation.
AIDS. 2011 Sep 10;25(14):1683-90.
HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.
Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, Kuhn L.
AIDS. 2011 Jul 31;25(12):1461-9.
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.
Schader SM, Colby-Germinario SP, Schachter JR, Xu H, Wainberg MA.
AIDS. 2011 Aug 24;25(13):1585-94.
Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
Gonzalez E, Ballana E, Clotet B, Esté JA.
AIDS. 2011 Aug 24;25(13):1557-83.
Resistance, resistance, go away: persistence of nevirapine-resistant HIV mutations in HIV-infected infants.
Paintsil E.
AIDS. 2011 Apr 24;25(7):997-9. No abstract available.
Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
Fogel J, Hoover DR, Sun J, Mofenson LM, Fowler MG, Taylor AW, Kumwenda N, Taha TE, Eshleman SH.
AIDS. 2011 Apr 24;25(7):911-7.
Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.
Neogi U, Shet A, Shamsundar R, Ekstrand ML.
AIDS. 2011 May 15;25(8):1123-6.
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.
Latinovic O, Le N, Reitz M, Pal R, DeVico A, Foulke JS, Redfield RR, Heredia A.
AIDS. 2011 Jun 1;25(9):1232-5.
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
Métifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, Marchand C, Pommier Y.
AIDS. 2011 Jun 1;25(9):1175-8.
Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala.
Ndembi N, Hamers RL, Sigaloff KC, Lyagoba F, Magambo B, Nanteza B, Watera C, Kaleebu P, Rinke de Wit TF.
AIDS. 2011 Apr 24;25(7):905-10.
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina JM, Ruxrungtham K, Workman C, Van De Casteele T, De Doncker P, Lathouwers E, Tomaka F.
AIDS. 2011 Apr 24;25(7):929-39.
The rise and fall of methicillin-resistant Staphylococcus aureus infections in HIV patients.
Hidron AI, Moanna A, Rimland D.
AIDS. 2011 Apr 24;25(7):1001-3.
Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, de Castro N, Molina JM, Kuritzkes DR.
AIDS. 2011 Mar 13;25(5):665-9.
The impact of HIV drug resistance testing on changes to treatment.
Bansi L, Smith C, Phillips A, Kirk S, Geretti AM, Johnson M, Mackie N, Post F, Gazzard B, Dunn D, Sabin C; UK Collaborative HIV Cohort (CHIC) Study and the UK Collaborative Group on HIV Drug Resistance (HDRD).
AIDS. 2011 Mar 13;25(5):603-10.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on